David Inwards
Overview
Explore the profile of David Inwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Abeykoon J, Zanwar S, Ansell S, Gertz M, Kumar S, Manske M, et al.
Br J Haematol
. 2019 Aug;
188(3):394-403.
PMID: 31468508
Ibrutinib-related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly outside of trials. We report on 80 patients [previously treated, n = 67 (84%), treatment-naïve, n = 13 (16%)] with WM,...
12.
Ahmed S, Kanakry J, Ahn K, Litovich C, Abdel-Azim H, Aljurf M, et al.
Biol Blood Marrow Transplant
. 2019 May;
25(9):1859-1868.
PMID: 31132455
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes...
13.
Witzig T, Inwards D
Blood
. 2019 Apr;
133(24):2570-2574.
PMID: 30967367
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is...
14.
Epperla N, Ahn K, Litovich C, Ahmed S, Battiwalla M, Cohen J, et al.
J Hematol Oncol
. 2019 Jan;
12(1):6.
PMID: 30630534
Background: There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here...
15.
Zanwar S, Abeykoon J, Ansell S, Gertz M, Dispenzieri A, Muchtar E, et al.
Leukemia
. 2018 Oct;
33(3):790-794.
PMID: 30315235
No abstract available.
16.
Smith S, Godfrey J, Ahn K, DiGilio A, Ahmed S, Agrawal V, et al.
Cancer
. 2018 Apr;
124(12):2541-2551.
PMID: 29645093
Background: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies...
17.
Casulo C, Friedberg J, Ahn K, Flowers C, DiGilio A, Smith S, et al.
Biol Blood Marrow Transplant
. 2017 Dec;
24(6):1163-1171.
PMID: 29242111
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood...
18.
Rosenthal A, Dueck A, Ansell S, Gano K, Conley C, Nowakowski G, et al.
Am J Hematol
. 2017 Feb;
92(5):467-472.
PMID: 28230270
Patients with indolent non-Hodgkin lymphoma (NHL) have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in...
19.
Fenske T, Ahn K, Graff T, DiGilio A, Bashir Q, Kamble R, et al.
Br J Haematol
. 2016 Mar;
174(2):235-48.
PMID: 26989808
For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using...
20.
DSouza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al.
Blood
. 2012 May;
120(1):56-62.
PMID: 22611150
The POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose...